Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine

Area of Science:

• * Virology and Immunology
• * Vaccinology
• * Public Health

Background:

• * The 2009 pandemic influenza A (H1N1) virus emerged in Mexico, leading to substantial global mortality and years of life lost, particularly among younger populations.
• * This pandemic's impact was comparable to major influenza pandemics of the past (1957, 1968).

Purpose of the Study:

• * To review available data on the monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine, Pandemrix™.
• * To assess the vaccine's immunogenicity and safety profile in the context of the ongoing influenza pandemic.

Main Methods:

• * Review of existing data on Pandemrix™ vaccine.
• * Analysis of immunogenicity across various age groups, including infants and children.
• * Evaluation of the vaccine's safety profile during the pandemic.

Main Results:

• * Pandemrix™ demonstrates high immunogenicity in all evaluated age groups, including children under 3 years.
• * The vaccine exhibits an acceptable safety profile within the pandemic context.
• * The novel adjuvant necessitates further investigation.

Conclusions:

• * Pandemrix™ is a promising vaccine candidate for pandemic influenza A (H1N1) 2009, showing good immunogenicity and safety.
• * Further research, including robust post-marketing surveillance, is essential to fully understand the long-term safety, immunogenicity, and effectiveness of Pandemrix™ due to its novel adjuvant.